Author

L. Litovchick

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Organism:human· 3 Research Focus:cancer & tumor microenvironment· 2 Assay:proteomics· 2 Assay:bulk RNA-seq· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Research Focus:drug response / drug discovery· 1

Frequent Co-Authors

B. Hu· 2 shared A. N. Iness· 1 shared A. Pajimola· 1 shared A. Witt· 1 shared E. J. Peterson· 1 shared E. Katsuta· 1 shared F. Sesay· 1 shared J. C. Harrell· 1 shared

Activity by Year

2018-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

B. Hu

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Inhibition of LATS Kinases in Ovarian Cancer Activates Cyclin D1/CDK4 and Decreases DYRK1A Activity

F. Sesay, S. Saini, A. Pajimola, A. Witt, B. Hu, J. Koblinski, L. Litovchick

This study shows that inhibiting LATS kinases in ovarian cancer cells activates cyclin D1/CDK4 and reduces DYRK1A activity, promoting tumor growth.

bioRxiv · Dec 6, 2022 · PreprintCancer Biology

Exploitation of sulfated glycosaminoglycan status for precision medicine of platinums in triple-negative breast cancer

J. D. Hampton, E. J. Peterson, S. J. Katner, T. H. Turner, M. A. Alzubi, J. C. Harrell, M. G. Dozmorov, P. J. Gigliotti, V. Kraskauskiene, M. Shende, M. O. Idowu, M. Puchalapalli, B. Hu, L. Litovchick, E. Katsuta, , J. E. Koblinski

This study identifies sulfated glycosaminoglycan (sGAG) levels as a biomarker predicting response to Triplatin in triple-negative breast cancer (TNBC), showing improved efficacy compared to carboplatin in sGAG-high tumors.

bioRxiv · May 5, 2021Pharmacology & Toxicology

The cell cycle regulatory DREAM complex is disrupted by high expression of oncogenic B-Myb

A. N. Iness, J. Felthousen, V. Ananthapadmanabhan, K. Z. Guiley, M. Dozmorov, S. M. Rubin, L. Litovchick

This study shows that B-Myb disrupts the DREAM complex by affecting LIN52 protein levels and DYRK1A kinase activity, contributing to cancer progression.

Oncogene · Sep 11, 2018Peer-reviewedCancer Biology